To assess whether pharmacological targeting of PEPCK1 offers a preventive and therapeutic strategy against HDS-induced tumorigenesis in vivo, we employed hydrazinium sulfate (HS), an inhibitor of PEPCK, in an attempt to suppress tumor progression by inhibiting PEPCK1 [38]. Here, PCK1 is linked to neoplasm.